Aviapen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aviapen

Aviapen is a core anti-infective agent whose active ingredient is Benzylpenicillin, which is chemically synonymous with Penicillin G (PenG). It is classified as a natural penicillin and a beta-lactam antimicrobial drug. The critical importance of this substance in medical therapy is clinically recognized worldwide, with Benzylpenicillin consistently included on the Model List of Essential Medicines.


Quick Facts

Property Description
Active ingredient Benzylpenicillin (Penicillin G)
Form Sterile Crystalline Powder (for reconstitution)
Pharmacological class Beta-Lactam Antimicrobial, Antibiotic
Common use Eliminating susceptible bacterial pathogens
Origin Natural Penicillin

What Type of Medicine is Aviapen?

Aviapen is fundamentally an antibiotic belonging to the oldest pharmacological group of anti-infective medications, the penicillins. The drug is always a prescription-only (Rx) medicine, reflecting the need for professional oversight in its administration, which is standard for potent anti-infective agents. It is utilized for its bactericidal effect, meaning it actively kills susceptible bacteria, rather than just suppressing their growth.

Composition, Origin, and Preparation Form

The composition is centered on the single active substance, Benzylpenicillin, which is supplied as a highly soluble salt, such as the potassium or sodium form. The drug is provided as a sterile crystalline powder for reconstitution, due to the ingredient's chemical instability in extended liquid form. This powder must be dissolved in an aqueous solution right before use, preparing it for administration via parenteral routes (intravenously or intramuscularly) to ensure rapid systemic delivery.

General Purpose and Action Type

The general purpose of Aviapen is the direct and efficient elimination of susceptible bacterial pathogens in the body, such as bacteria causing acute infections. Its mechanism is highly targeted: it actively destroys bacteria by inhibiting the synthesis of the microbial cell wall. This powerful, targeted action ensures a rapid reduction in the bacterial load necessary for resolving the infectious process.

Regulatory References

  1. World Health Organization's Model List of Essential Medicines

What side effects are possible with Aviapen?

Possible Side Effects and Safety Information

The official regulatory safety profile for Benzylpenicillin is formally structured around high-level adverse reactions classified by frequency and system involvement. The primary safety concern documented in regulatory texts is hypersensitivity, which ranges from common manifestations like rashes and fever to potentially fatal anaphylactic shock, an event classified as rare but serious. This risk dictates a foundational safety constraint: the medicine is contraindicated for individuals with a known history of penicillin allergy [as stated in FDA and EMA prescribing documents].

Adverse reactions are formally grouped by System-Organ Class (SOC), including effects on the Immune System, Blood and Lymphatic System (e.g., leucopenia), and Nervous System. Within the Nervous System category, high concentrations are officially associated with potential neurotoxicity, including documented instances of convulsions or seizures.

Official Safety Considerations

The most significant population-specific safety note concerns Renal Impairment. Regulatory documents state that reduced drug clearance in patients with impaired kidney function increases the risk of severe toxicity, particularly neurotoxicity and electrolyte imbalances, necessitating cautious application. Exposure-related patterns are also noted, such as the acute Jarisch-Herxheimer Reaction, which may occur shortly after the initial dose when treating specific spirochete infections.

For high-dose, extended treatment, official prescribing information advises for the formal monitoring of electrolyte balance, renal function, and blood counts, reflecting documented safety requirements to mitigate risks associated with prolonged systemic exposure.

Overdose and Emergency Response

Aviapen Overdose and when to seek help

Official regulatory information describes overdose with Aviapen (Benzylpenicillin/Penicillin G) as primarily affecting the Central Nervous System (CNS). Overdose is documented to lead to neuromuscular hyperirritability, including signs such as myoclonus (muscle twitching), hyperreflexia, and mental confusion.

Documented Manifestations and Emergency Action

Documented Overdose Manifestations Emergency Action Mandate
Convulsive seizures Seek immediate medical attention
Coma or inability to awaken Contact emergency services immediately
Severe neurotoxicity Discontinue the medicine

Overdose manifestations, including seizures, are more commonly documented with massive doses, particularly in patients with severe renal impairment due to reduced drug clearance. This population-specific risk is officially noted in prescribing information. The regulatory guidance states that the drug must be immediately discontinued upon suspected overdose.

Management procedures officially described include initiating symptomatic and supportive treatment. No specific antidote for Benzylpenicillin overdose is known. Hemodialysis is listed in regulatory documentation as a procedure that may be utilized to reduce high systemic concentrations.

Therapeutic Uses of Aviapen

What Aviapen Treats: Main Uses and Benefits

Aviapen (Benzylpenicillin/Penicillin G) is an antimicrobial agent applied across domains where additional symptomatic support is needed for acute and severe bacterial infections. It is commonly used to address susceptible pathogens in conditions presenting with systemic or localized discomfort.

Core Therapeutic Focus

This medication is commonly used in clinical settings that involve acute or unstable symptom patterns arising from widespread systemic infection, such as septicaemia (blood poisoning) or bacterial infections of the protective membranes surrounding the brain (meningitis). It is also relevant in conditions characterized by periods of heightened symptoms from deep tissue infections like osteomyelitis (bone infection) and specific spirochetal diseases like syphilis across various stages. Its role is to provide support to ease symptoms related to heightened physiological activity and organ-specific functional stress, and is relevant when supportive symptom management is appropriate.

Aviapen is generally considered relevant for easing symptoms related to recurrent or episodic manifestations. It is applied in prophylactic scenarios, primarily in patients with a history of rheumatic fever. This application helps maintain a sense of stability when symptoms are more noticeable and contributes to improved comfort.

Quick Fact: Support for Systemic Discomfort Aviapen is commonly used in conditions where symptoms create noticeable physiological strain, assisting with managing symptoms related to systemic imbalance and heightened physiological activity.

Eligibility and Restrictions for Use

The eligibility for this medicine (Aztreonam and Avibactam, regulatory trade name EMBLAVEO) is strictly defined by official regulatory bodies, focusing on patient characteristics and clinical state.

Contraindications and Restrictions

Classification Condition or Population
Contraindicated Patients with known hypersensitivity to the components (aztreonam or avibactam).
Age-Restricted Use is authorized only for adult patients, defined as those 18 years of age and older.
Condition-Specific Use is limited to treating infections that are proven or strongly suspected to be caused by susceptible bacteria.
Limited Use For complicated intra-abdominal infections, the medicine is indicated only in patients who have limited or no alternative treatment options.
Special Consideration Patients with renal impairment (creatinine clearance leq 50 mL/min) require close monitoring and mandated dosage adjustments due to the way the components are eliminated by the kidneys.

Official labeling does not formally list pregnancy and lactation as a status of contraindication or absolute prohibition. Therefore, the use is restricted to the adult population and those without documented hypersensitivity, with specific constraints applied for compromised renal function or limited alternative treatments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define a set of interactions for Benzylpenicillin (Penicillin G) based on altered drug elimination and combined pharmacologic effects.

Official Interaction Statements

Interaction Type Interacting Substance(s) / Category Regulatory Classification & Documented Effect
Formal Regulatory Prohibition Methotrexate Contraindicated combination; Penicillins reduce the renal clearance of Methotrexate, which elevates its systemic exposure.
Renal Excretion Interference Probenecid, NSAIDs (e.g., Acetylsalicylic acid) Leads to higher and prolonged plasma concentrations of Benzylpenicillin by inhibiting its renal tubular secretion.
Pharmacodynamic Alterations Oral Anticoagulants Co-administration is documented to increase the anticoagulant activity, which elevates the risk of haemorrhages.
Pharmacodynamic Antagonism Tetracyclines (a bacteriostatic class) Use should be avoided as the agent may antagonize the bactericidal effect of penicillin.
Excipient-Based Caution Soy phospholipids (in some formulations) Risk of hypersensitivity reactions (e.g., anaphylactic shock) in patients with documented soy or peanut allergy.

Population-Specific Interaction Notes

Elimination of Benzylpenicillin is officially documented to be considerably delayed in patients with impaired renal function, which alters the drug's exposure. This reduced clearance is noted to be further complicated when hepatic insufficiency is also present. Regulatory agencies classify the Methotrexate pairing as a contraindicated combination due to the clinically significant risk associated with altered clearance.

Mechanism of Action

How Aviapen Works

Benzylpenicillin's mechanism centers on the selective inhibition of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes (DD-transpeptidases) essential for building the rigid peptidoglycan structure of the cell wall. The drug acts as an irreversible covalent inhibitor, permanently deactivating these PBPs by binding to their active site. This molecular interference halts the final cross-linking step of the wall, an action that demonstrates selective toxicity to the microbial cell.

Blocking cell wall assembly initiates a critical cascade: the compromised structure can no longer withstand the high internal osmotic pressure of the bacterial cell. This pressure difference leads to water rushing in and causing the cell to swell and burst (lysis). The resulting physiological effect is the rapid and direct death of susceptible bacterial cells, a mechanism classified as bactericidal, leading to the reduction in susceptible bacterial cell count.

This mechanism is physiologically constrained by bacterial counter-mechanisms, including the production of beta-lactamase enzymes that chemically cleave the drug's beta-lactam ring, and the development of modified PBPs with reduced binding affinity for the drug.

Dosage and Administration Information

Instruction Map: How to use Aviapen — Official Administration Guidelines

The use of Aviapen (Benzylpenicillin/Penicillin G) is governed by specific instructions focusing exclusively on parenteral administration. This means the medicine is given either by intravenous (IV) injection or infusion, or by intramuscular (IM) injection. The crystalline powder form requires fresh reconstitution with a suitable diluent immediately prior to use; diluent selection is crucial for patients with pre-existing heart or kidney conditions.


The dosing schedule is highly dependent on the preparation used. The short-acting form is administered frequently, typically every 4 to 6 hours, to maintain drug levels. For severe conditions, the daily dose for adults can reach up to 14.4 g (24 Million International Units). Conversely, long-acting preparations, which are mandatory for certain periodic regimens (e.g., prophylaxis), are given less often, such as once every three to four weeks.


Official guidelines mandate dose adjustments for specific patient populations. The dosage and interval must be reduced in patients with renal (kidney) impairment due to delayed clearance of the drug. Furthermore, long-acting formulations must be given via deep IM injection only and are strictly prohibited from being administered intravenously or intra-arterially. For high-dose IV administration, the infusion must be slow and controlled, often taking 30 to 60 minutes.

Recent Clinical Evidence

Research evidence / Overview of studies for Aviapen


Evidence for use in Necrotic Enteritis

Aviapen (or its active component, Penicillin G) was studied for use in animals with necrotic enteritis, a condition associated with acute or disruptive episodes in the digestive system. Research has explored how symptoms and outcomes related to systemic or functional imbalance evolved in the observed populations.

Research for this condition was evaluated in observational settings evaluating daily-life functioning, applicable in trials assessing short-term or episodic symptom patterns. The findings describe patterns observed in the studies over defined time intervals. For instance, research examined outcomes related to inflammatory or irritative states.

It is important to note that the results apply only to the populations studied, and evidence quality varies across studies. For some reports, sample sizes were modest, meaning the full range of potential patterns may not be captured.

Evidence for use in Respiratory Tract Infections

Aviapen was evaluated in studies focused on animals experiencing respiratory tract infections, conditions characterized by fluctuating or episodic manifestations. These studies was studied for outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Research examined the compound in research contexts involving fluctuating or unstable symptoms, exploring how temporary physiological imbalance responded when Aviapen was studied for. Research provides insight into short-term changes and monitors responses over defined time intervals. This research contributes to the broader evidence landscape.

However, certain aspects remain under investigation. While the evidence was observed in some studies, comparative evidence is lacking in certain areas, making it difficult to fully contextualize the findings. Data are still emerging in this area.


Long-term studies and follow-up

The research has also explored the longer-term course of the conditions and the patterns seen after treatment with Aviapen. Studies that monitored animals over extended periods provide context but not individual predictions regarding the durability of the observed patterns.

For the conditions Aviapen was studied for, research exploring follow-up outcomes remains an area where more information is needed. While some studies look beyond the initial observation period, long-term effects are not fully established, and follow-up durations were limited in many reports. This evidence highlights what is known—and what is still uncertain—about patterns of stability and potential reoccurrence over extended time frames.

Evidence in special populations

Research has explored the use of Aviapen in special populations because responses may differ based on age or existing health issues. These groups include younger animals or those with other comorbid conditions.

Research was evaluated in settings that included specific subgroups, such as young animals, where data for certain groups remain insufficient. The evidence was studied for symptom patterns, but subgroup findings are uncertain due to variations in how these specific populations was studied for. It is important to remember that these findings describe group patterns, not personal outcomes.


What is still uncertain about Aviapen

The overall body of research, while informative, points to several areas where research is ongoing and more information is needed. Findings were mixed or inconsistent in certain small-scale studies exploring specific types of outcomes reflecting daily functioning or activity level.

One key area is the lack of extensive research exploring all potential research scenarios and populations. As noted, comparative evidence is lacking in some areas, and data are still emerging regarding the full range of animals and specific condition variants. The evidence is limited in characterizing all potential patterns of response, and the certainty surrounding some long-term findings remains low. This research highlights what is known—and what is still uncertain.

Key Studies & References

  1. Necrotic Enteritis in Poultry - Merck Veterinary Manual
  2. Depletion of penicillin G residues in sows after intramuscular injection final - Pork Checkoff (Relevant for long-term/depletion data)
  3. Label: PENICILLIN G POTASSIUM powder, for solution - DailyMed (FDA-Approved Monograph/Label)

Frequently Asked Questions (FAQ)

Common questions about Aviapen (FAQ)

Q: What happens if a person who shouldn't use Aviapen takes it by mistake?

Official regulatory documents emphasize that Aviapen is contraindicated, meaning it should not be used, in patients who have a known history of allergy to penicillin. This restriction is in place because using the medicine in this population carries a significant risk of severe hypersensitivity reactions, which can include life-threatening anaphylactic shock.

Q: Can people with liver problems use Aviapen?

Regulatory product information notes that Aviapen is primarily eliminated by the kidneys. While dosage adjustments are specifically mandated for patients with kidney problems, official documentation also states that reduced drug clearance in those with impaired kidney function can be further complicated when hepatic (liver) insufficiency is also present. This indicates that professionals must consider this factor when evaluating eligibility and determining the appropriate administration conditions.

Q: What kind of studies led to Aviapen being approved?

Regulatory information classifies Aviapen as a prescription-only medicine, which reflects that it has undergone the standard clinical trial process required for government approval. This process includes studies designed to demonstrate that the medicine is effective for its approved uses and that its benefits are considered to outweigh its established risks.

Q: Is Aviapen considered a long-term treatment?

Regulatory information indicates that the active ingredient in Aviapen is available in both short-acting and long-acting preparations. The existence of long-acting forms, which are specifically used for certain periodic regimens over extended periods, shows that this medicine is used both for acute infections and for chronic or long-term preventative protocols.

Q: Does Aviapen interact with common pain relievers like ibuprofen?

Yes, official documents address interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes ibuprofen. These medicines can affect the way Aviapen is cleared from the body, leading to higher and prolonged plasma concentrations of the antibiotic. This change in concentration is why official caution and potential adjustments are noted when these medicines are used together.

Q: Is it common to have certain side effects when starting Aviapen?

Regulatory information explicitly notes the acute Jarisch-Herxheimer Reaction may occur shortly after the initial dose when treating specific spirochete infections. This reaction is related to the initial action of the medicine against certain bacteria, which is noted in regulatory information.

Q: Are there special warnings for people with heart conditions who use Aviapen?

Official guidelines state that diluent selection is crucial for patients with pre-existing heart or kidney conditions. This warning is necessary because the diluents used to mix the powder can affect the body's electrolyte balance, which is a concern for individuals with heart issues.

Q: How long does the effect of Aviapen last?

The duration of effect depends on the specific preparation used. The short-acting form has a short elimination half-life, typically requiring frequent administration (e.g., every four to six hours) to maintain adequate levels. Conversely, long-acting preparations are specifically formulated to maintain therapeutic drug levels for up to several weeks following a single injection.

Q: Do I need to take Aviapen every day?

The need for daily administration depends on the form of the medicine prescribed. While the short-acting preparation is administered frequently, long-acting preparations are given less often, sometimes only once every three to four weeks, for specific treatment regimens.

Q: Can I take Aviapen with food?

The answer is straightforward because Aviapen is not an oral medicine. It is supplied as a sterile crystalline powder that is mixed into a solution and given via parenteral routes (injection or infusion). Therefore, its administration is not affected by food intake.

Q: Does Aviapen cause weight gain or loss?

When reviewing the adverse reaction listings by body system, official product information does not typically include weight gain or loss in the high-frequency or commonly documented categories. Safety reporting focuses primarily on effects related to the immune system, blood, and the nervous system.

Q: Can Aviapen affect my sleep?

The regulatory side effect profile lists potential effects on the Nervous System, which can include severe events like neurotoxicity and convulsions. However, general disturbances to sleep, such as insomnia or drowsiness, are not listed in the provided high-level categories of officially documented reactions.

Q: Is Aviapen safe for older adults?

Regulatory information notes that because older adults are more likely to have reduced kidney function, their individual needs for monitoring and potential dosage adjustments must be considered. This caution is based on the way the drug is cleared from the body.

Q: Can children or teenagers take Aviapen?

The regulatory eligibility for this medicine is age-restricted. Official product information authorizes use only for adult patients, which are defined as those 18 years of age and older. This age restriction means the medicine is not authorized for use in children or teenagers under 18 years of age.

Q: Is Aviapen safe to use during pregnancy?

Official documentation describes the use of the drug during pregnancy as being restricted to situations where professional assessment determines a clear need, balancing potential benefit against risk. In some jurisdictions, the active ingredient is classified in a category suggesting that the risk of causing fetal malformations is considered unlikely.

Q: What is the research evidence for how well Aviapen works?

Studies have examined outcomes related to changes in inflammatory states and physical discomfort in the populations studied for certain infections. Regulatory summaries note that the available evidence quality is noted to vary and that comparative data against other treatments may be lacking in certain areas.

Q: Are there studies comparing Aviapen to a placebo?

Regulatory research summaries indicate that comparative evidence is lacking in certain areas of study. However, for a drug like this, the official determination of effectiveness is based on trials, and findings may have been mixed or limited in small-scale studies exploring specific patient outcomes.

Q: Why do doctors prescribe Aviapen for a long period?

The need for long-term use is associated with the long-acting preparations of the medicine. These are used for mandatory, periodic regimens (e.g., every three to four weeks) for certain infections, where the goal is often prophylaxis (preventative treatment) rather than treating an acute infection.

Q: Can Aviapen be crushed or split?

No, Aviapen is not an oral tablet or capsule meant for splitting. It is supplied as a sterile crystalline powder intended to be mixed into a liquid solution for injection or infusion. Therefore, it is not intended to be crushed or split.

Q: Do different strengths of Aviapen have different side effects?

Official safety notes indicate that higher systemic exposure is associated with increased risk of certain adverse events. Specifically, high concentrations of the medicine are linked to an increased risk of potential neurotoxicity, which includes complications such as convulsions. This suggests that the total dose administered may influence the risk of certain side effects.

Q: How long does Aviapen stay in the body?

The time the active ingredient stays in the body varies significantly by the preparation used. The short-acting form has a very short elimination half-life (e.g., around 30 minutes) requiring frequent dosing. The long-acting forms, however, are specifically designed to be eliminated much slower, maintaining therapeutic levels for several weeks.

Q: Does Aviapen have a risk of dependence or addiction?

No. Official regulatory drug information for the active ingredient confirms it is Not a controlled medication and is not associated with any documented risk of dependence or addiction.

Q: Is there a generic version of Aviapen available?

Yes. The active ingredient in Aviapen, Benzylpenicillin (Penicillin G), is a foundational and widely used medicine. It is available globally in lower-cost generic forms.

Q: Is Aviapen a controlled substance?

No. The active ingredient, Penicillin G, is classified by regulatory bodies as Not a controlled medication. It is always a prescription-only medicine, but it does not carry the control status associated with risk of dependence.

Q: Can Aviapen affect my ability to drive?

Official safety information includes warnings related to potential effects on the Nervous System. Since these warnings mention neurotoxicity and the possibility of convulsions or seizures, the official safety documentation contains warnings that these potential effects may lead to impaired ability to drive or operate machinery.

How should Aviapen be stored and disposed of?

Storage and Disposal Requirements

Aviapen (Benzylpenicillin Powder for Injection) has strict storage rules defined by regulatory documents, which vary before and after reconstitution. The unopened sterile powder must be stored in the original packaging, protected from light and moisture, and kept below 25 C or 30 C, depending on the official label. The product must not be frozen at any point.

Once the powder is mixed, the resulting solution is highly unstable and is intended for immediate use. If storage is necessary, the solution has a highly restricted shelf-life, typically no more than 24 hours, when kept under refrigerated conditions (2 C to 8 C).

All medicine must be stored out of the sight and reach of children. Any unused or expired product must be disposed of according to local pharmaceutical waste requirements. Associated sharps (needles or vials) must be discarded in a dedicated sharps container, in line with official disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aviapen found in:

A-Z Index: